Page last updated: 2024-12-07

renzapride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Renzapride is a dopamine D2 and serotonin 5-HT4 receptor agonist. It was initially developed as an antipsychotic agent, but its clinical development was halted due to adverse effects. However, recent research has investigated its potential therapeutic applications for conditions like Parkinson's disease, irritable bowel syndrome, and Alzheimer's disease. Renzapride exhibits promising effects in preclinical models for these conditions by improving motor function, modulating gastrointestinal motility, and enhancing cognitive function. The compound has been synthesized through a multi-step process involving the coupling of a substituted benzamide derivative with a substituted piperazine moiety.'

Cross-References

ID SourceID
PubMed CID119574
SCHEMBL ID17037
MeSH IDM0150281

Synonyms (30)

Synonym
atl-1251
112727-80-7
PDSP2_001315
renzapridum [inn-latin]
benzamide, 4-amino-n-1-azabicyclo(3.3.1)non-4-yl-5-chloro-2-methoxy-, endo-
renzapride [inn]
renzaprida [inn-spanish]
4-amino-n-1-azabicyclo(3.3.1)non-4-yl-5-chloro-2-methoxybenzamide endo-
renzapride
renzapride [inn:ban]
4-amino-n-[(4r,5s)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide
unii-9073c0w4e9
9073c0w4e9 ,
((+-)-endo)-4-amino-5-chloro-2-methoxy-n-(1-azabicyclo(3.3.1)non-4-yl)benzamide
renzaprida
renzapridum
renzapride [who-dd]
((+/-)-endo)-4-amino-n-(1-azabicyclo(3.3.1)non-4-yl)-5-chloroanisamide
renzapride [mart.]
renzapride [mi]
rel-4-amino-n-(1r,4s,5r)-1-azabicyclo(3.3.1)non-4-yl-5-chloro-2-methoxybenzamide
SCHEMBL17037
benzamide,4-amino-n-(1r,4s,5r)-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy-,rel-
benzamide, 4-amino-n-(1r,4s,5r)-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy-, hydrochloride (1:1), rel-
Q68414
DTXSID301318522
147822-02-4
147822-01-3
(r)-renzapride
AKOS040756481

Research Excerpts

Overview

Renzapride is a novel drug currently under clinical evaluation for the treatment of irritable bowel syndrome (IBS)

ExcerptReferenceRelevance
"Renzapride is a novel drug currently under clinical evaluation for the treatment of irritable bowel syndrome (IBS). "( Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome.
Scarpellini, E; Tack, J, 2008
)
3.23

Actions

ExcerptReferenceRelevance
"Renzapride did not inhibit the major CYP drug-metabolizing enzymes CYP2C9, CYP2D6, CYP1A2, CYP2A6, CYP2C19, CYP2E1 or CYP3A4 at concentrations consistent with use in a clinical setting."( Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.
Hickling, RI; Meyers, NL, 2008
)
1.35

Pharmacokinetics

ExcerptReferenceRelevance
"To compare COVs for bowel function with pharmacodynamic (PD) colonic transit geometric center (GC) as endpoints in lower FGID studies."( Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations.
Burton, D; Camilleri, M; Zinsmeister, AR, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
"To identify an appropriate dosage of renzapride (a 5-HT(4) receptor full agonist/5-HT(3) receptor antagonist) to treat abdominal pain/discomfort in patients with constipation-predominant irritable bowel syndrome."( Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting.
George, AM; Hickling, RI; Meyers, NL, 2008
)
0.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (68)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (19.12)18.7374
1990's38 (55.88)18.2507
2000's11 (16.18)29.6817
2010's6 (8.82)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.64 (24.57)
Research Supply Index4.42 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index42.08 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (17.14%)5.53%
Reviews6 (8.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (74.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase III, Multicenter, Open Label, Extension Study to Evaluate the Long-Term Safety of Renzapride 4 mg Once Daily in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C) [NCT00607971]Phase 3939 participants (Actual)Interventional2006-04-30Terminated(stopped due to Terminated due to insufficient efficacy over placebo in Study ATL1251/038/CL.)
A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (c-IBS) [NCT00268879]Phase 31,821 participants (Actual)Interventional2005-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]